Best Stocks Under $10 Right Now → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Written by MarketBeat StaffAugust 1, 2022How Is a Company’s Share Price Calculated?Should Investors Buy Stocks Under $10?What Are the Rewards of Stocks Under $10?What Are the Risks of Buying Stocks Under $10?What Are the Best Stocks Under $10?A common mistake among novice investors is confusing an undervalued stock with a cheap stock. When a stock trades under $5 (often called penny stocks), it can be easy for an investor to understand why the stock carries such a low price. But when a stock trades below $10, a little more research is required. This is particularly true when the broader market is in a sell-off. Before attempting to buy stocks that are trading for less than 10 dollars, there are some important things to know. How Is a Company’s Share Price Calculated? If you’re an experienced investor this is just a basic review. But if you’re a relatively new investor this may help answer a lot of questions. To understand why buying stocks under $10 can come with an elevated risk you need to understand how a company’s stock price is calculated. There are two data points to look for. The first is a company’s market capitalization (or market cap). That is a rough estimation of how much a company is worth. The second number is the number of outstanding shares (also called shares outstanding – the meaning is the same). This is, as the name suggests, the number of common shares available to be bought. To calculate a company’s stock price, you divide the company’s current market capitalization by its number of outstanding shares. Here’s an example that keeps the math easy. A stock that is valued at $100 million and has 1 million outstanding shares has a share price of $100. But a stock that is valued at $100 million and has 100 million outstanding shares has a share price of $10. The important thing to take away from that example is a stock’s price does not necessarily reflect the market value of the company. Now here’s a real world example. On March 27, General Electric (NYSE:GE) had a market cap of $66.37 billion. The company had 8.74 billion outstanding shares. When you divide the market cap by the outstanding shares you get 7.59. 66.37/8.74 = 7.59 This means at that moment, one share of GE stock was valued at $7.59. Should Investors Buy Stocks Under $10? The simple answer is “Of course you should.” A common fallacy among even the most experienced investors is failing to understand the difference between a stock that is cheap and one that is undervalued. It’s an interesting aspect of human psychology. A stock that is trading at $200 could decline by 25% and investors will swoop in to buy it “on sale”. But if a $12 stock drops 20% it becomes untouchable. The problem with this approach is it assumes that a high price is good and a low price is bad. And in fairness, that can be true. Many stocks that trade under $10 do so because they present obvious and fundamentally problematic issues that are suppressing their growth. So if you’re an investor who is looking to buy stocks under $10 is be sure you’re ready, and able, to do some research. Simply throwing your hard-earned money at a stock because you’ve heard the mantra “buy low, sell high” is foolish. But the same can be said of investing in any stock. And if you’re reading this article, I hope you already understand that stocks over time can be an excellent and sound investment. Stock prices, no matter the price, can fluctuate wildly. But over time, investing in stocks has proven to be the most reliable path to reaching your financial goals. And the simple truth is that a stock that is trading under $10 can offer you the ability to make huge gains. But that is, if you know what to look for. Fortunately, in this article, we’ve done a lot of that research for you. But there is one caveat about investing in stocks under $10. This should only make up a small portion of the stock portion of your portfolio. The majority of your investment in equities (another name for stocks) should focus on solid, stable companies. And depending on your investment style, you should look for companies that pay a dividend. You should also not invest in stocks under $10 to replace money you have set aside in bonds or cash. This should be money that you are already investing in the market. What Are the Rewards of Stocks Under $10? The reward of buying stocks under $10 is the opportunity for growth. If you can buy 1000 shares of a stock that is trading at $8, you would only need the stock to increase in value by $8 to double your investment. If you were That, however, is easier said than done. And many investors have seen that $8,000 investment evaporate as they bought shares of a falling knife. Still, if investors can find the right stock, stocks under $10 are one of the best ways to capture a significant gain without a large investment. That brings up a second point. Stocks under $10 are more accessible for investors without a lot of money to put into the market. Robinhood and other trading apps are designed on this principle. If you only have a small amount of money to invest, you don’t have to put all your eggs in one basket. In practical terms, and investor with $10,000 to invest could buy over 150 shares a stock that is currently trading below $7 a share. This also makes stocks under $10 a great option for diversification. Not only can you look at different sectors, but you can also dabble in international stocks. What Are the Risks of Buying Stocks Under $10? Here are some of the most common risks of buying stocks under $10: Share dilution - Generally, the number of outstanding shares is driven by simple supply and demand. A company that issues a solid earnings report, or comes out with a new product, etc. will see their outstanding shares decline because there will be more buyers than sellers.In other words, the stock is harder to buy. If an investor wants to buy it, a seller will demand a higher price to let their shares go. And when there are more sellers than buyers, there will be a higher number of outstanding shares. In other words, sellers have to accept a lower price for the shares they purchased to entice a buyer to buy.However, when a company gets into financial trouble, it becomes difficult for them to get loans. When a company has limited free cash flow (FCF), they are seen as a credit risk. This simply means lenders believe there is a high probability that the company will default on the loan.When this happens, one strategy they may execute is to issue more shares. This almost always dilutes the value of the existing shares, which in turn drives the price down further. Increased competition - Young startup companies often have a first mover advantage. Because they are creating a new market, they have no competition and have no price pressure. However, as more competitors enter the market, a company may face pressure both on the price they charge and their profit margin. If the company is slow to adapt to the competition, their stock price may sink to extremely low levels. The company operates in a cyclical industry - A retailer may see their stock spike during the holiday season as investors anticipate greater revenue and profit. However, for the remainder of the year, the company may not be able to sustain that revenue. That’s another reason the stock may sink. The stock is low- to no-growth stock - If you look at the price history of a stock, it may just trade in a specific range. In that case, a stock under $10 may still be a worthwhile investment if it pays a nice dividend. What Are the Best Stocks Under $10? If you’ve followed this article and understand both the pros and cons of stocks under $10, let’s take a look at how you can put that information to work in the middle of one of the greatest stock sell-offs in history. On the one hand, there are a number of quality companies that have seen their share price reach uncomfortably low levels. But some of these stocks are in industries like hospitality that have been particularly affected by the coronavirus. And while these stocks are generally perceived to see increased, pent-up demand once the coronavirus threat recedes, it may be some time before this increased demand shows up in the stock price. Value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $10.00 requires investors to do their homework. At a price of under $10, these companies are not penny stocks. In fact many companies have a large market cap. But just because a stock is trading for a low price doesn’t make it a great value. One of the biggest assets an investor can have is time. If you’ve done your due diligence and believe in the overall financial health and direction of the company, buying stocks under $10 can be very profitable. If you have the time and patience to hold the stock through many economic cycles, here are some stocks to consider. 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment. Recent low priced stocks HeadlinesTake-Two Interactive, RBC Bearings rise; Cracker Barrel, Flowers Foods fall, Friday, 5/17/2024May 17, 2024 12:09 PMView Take-Two Interactive, RBC Bearings rise; Cracker Barrel, Flowers Foods fall, Friday, 5/17/2024Take-Two Interactive Software Offers 2nd Chance for InvestorsMay 17, 2024 9:45 AMView Take-Two Interactive Software Offers 2nd Chance for InvestorsDeere & Company’s Q2 Report: Strong Revenue, Cautious Outlook May 17, 2024 9:30 AMView Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook Analysts Still Want Double-Digit Upside Out of Applied MaterialsMay 17, 2024 9:12 AMView Analysts Still Want Double-Digit Upside Out of Applied MaterialsBaidu Stock Earnings Prove Ray Dalio Right about China?May 17, 2024 8:59 AMView Baidu Stock Earnings Prove Ray Dalio Right about China?3 Reasons Nvidia is on The Verge of a 4 Digit Stock PriceMay 17, 2024 8:39 AMView 3 Reasons Nvidia is on The Verge of a 4 Digit Stock Price3 Cheap Stocks That Shouldn’t Be SoApril 22, 2024 9:32 AMView 3 Cheap Stocks That Shouldn’t Be SoMore low priced stocks HeadlinesTop Headlines and Offers3 Affordable Stocks That Won’t Stay Down Much LongerMay 13, 2024 9:12 AMView 3 Affordable Stocks That Won’t Stay Down Much LongerWhat Wall Street Doesn’t Want You to Know About Alibaba StockMay 14, 2024 9:55 AMView What Wall Street Doesn’t Want You to Know About Alibaba Stock348 million Americans lives to END as we know it?From The Oxford Club(Ad)View 348 million Americans lives to END as we know it?The Electric Vehicle Market Just Made a Sudden Turn May 15, 2024 7:33 AMView The Electric Vehicle Market Just Made a Sudden Turn 3 Hot Stock Upgrades That Should Be on Your RadarMay 13, 2024 9:23 AMView 3 Hot Stock Upgrades That Should Be on Your RadarStock market today: Asian shares retreat after Wall St edges back from recordsMay 16, 2024 2:57 AMView Stock market today: Asian shares retreat after Wall St edges back from records348 million Americans lives to END as we know it?From The Oxford Club(Ad)View 348 million Americans lives to END as we know it?4 Small-Cap Energy Stocks Insiders are Buying May 15, 2024 8:09 AMView 4 Small-Cap Energy Stocks Insiders are Buying 5 Meme Stocks With a High Short InterestMay 14, 2024 7:00 AMView 5 Meme Stocks With a High Short InterestWhy These Companies Are Buying Back Stock LatelyMay 13, 2024 11:45 AMView Why These Companies Are Buying Back Stock LatelyMeme stocks are roaring again. This time may be differentMay 14, 2024 2:13 PMView Meme stocks are roaring again. This time may be differentThese 5 Penny Stocks Just Surged Double DigitsMay 16, 2024 8:35 AMView These 5 Penny Stocks Just Surged Double DigitsAll Headlines Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - Clean Energy FuelsNASDAQ:CLNEStock Price: $2.67 (+$0.05)P/E Ratio: -7.63Market Cap: $596.10 millionAverage Trading Volume: 1.63 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.60 (109.7% Upside)Clean Energy Fuels Corp. provides natural gas as alternative fuels for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Ocuphire PharmaNASDAQ:OCUPStock Price: $1.73 (-$0.00)P/E Ratio: -3.54Market Cap: $44.96 millionAverage Trading Volume: 213,074 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.75 (980.9% Upside)Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.#3 - PMV PharmaceuticalsNASDAQ:PMVPStock Price: $2.13 (-$0.02)P/E Ratio: -1.60Market Cap: $109.57 millionAverage Trading Volume: 539,017 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.75 (170.0% Upside)PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.#4 - Zura BioNASDAQ:ZURAStock Price: $6.27 (+$0.27)Market Cap: $270.17 millionAverage Trading Volume: 272,416 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.83 (200.4% Upside)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.#5 - Aquestive TherapeuticsNASDAQ:AQSTStock Price: $3.19 (-$0.09)P/E Ratio: -7.60Market Cap: $290.42 millionAverage Trading Volume: 2.18 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.00 (150.8% Upside)Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.#6 - Hecla MiningNYSE:HLStock Price: $6.09 (+$0.60)P/E Ratio: -40.60Market Cap: $3.81 billionAverage Trading Volume: 8.05 million sharesDividend Yield: 0.45%<Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.89 (13.2% Upside)Hecla Mining Company, together with its subsidiaries, provides precious and base metal properties in the United States, Canada, Japan, Korea, and China. The company mines for silver, gold, lead, and zinc concentrates, as well as carbon material containing silver and gold for custom smelters, metal traders, and third-party processors; and doré containing silver and gold. It flagship project is the Greens Creek mine located on Admiralty Island in southeast Alaska. Hecla Mining Company was incorporated in 1891 and is headquartered in Coeur d'Alene, Idaho.“Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now.#7 - ArdelyxNASDAQ:ARDXStock Price: $7.80 (+$0.01)P/E Ratio: -27.86Market Cap: $1.82 billionAverage Trading Volume: 6.07 million sharesConsensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.81 (64.3% Upside)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.#8 - KingfisherOTCMKTS:KGFHYStock Price: $6.59 (+$0.04)Market Cap: $6.16 billionAverage Trading Volume: 930,241 sharesDividend Yield: 2.43%<Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AKingfisher plc, together with its subsidiaries, supplies home improvement products and services primarily in the United Kingdom, Ireland, France, and internationally. The company also offers property investment, finance, digital, sourcing, and IT services. It also operates retail stores under the B&Q, Castorama, Brico Dépôt, Screwfix, TradePoint, and Koçtas brands. The company sells its products through stores and e-commerce channels. Kingfisher plc was incorporated in 1982 and is headquartered in London, the United Kingdom.#9 - BiodesixNASDAQ:BDSXStock Price: $1.57 (+$0.01)P/E Ratio: -2.85Market Cap: $180.06 millionAverage Trading Volume: 138,025 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.10 (97.5% Upside)Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.#10 - Granite Ridge ResourcesNYSE:GRNTStock Price: $6.49 (+$0.03)P/E Ratio: 14.42Market Cap: $848.50 millionAverage Trading Volume: 403,208 sharesDividend Yield: 6.64%<Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.45 (30.2% Upside)Granite Ridge Resources, Inc. operates as a non-operated oil and gas exploration and production company. It owns a portfolio of wells and acreage across the Permian and other unconventional basins in the United States. Granite Ridge Resources, Inc. is based in Dallas, Texas.#11 - LifeMDNASDAQ:LFMDStock Price: $7.79 (+$0.07)P/E Ratio: -10.53Market Cap: $329.44 millionAverage Trading Volume: 851,889 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.60 (48.9% Upside)LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.“Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now.#12 - easyJetOTCMKTS:ESYJYStock Price: $6.36 (-$0.52)P/E Ratio: 1.40Average Trading Volume: 11,498 sharesDividend Yield: 2.60%<Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AeasyJet plc operates as a low-cost airline carrier in Europe. The company engages in the provision of holiday packages; aircraft trading and leasing activities; development of building projects; financing and insurance business; and tour operator activities. easyJet plc was founded in 1995 and is headquartered in Luton, the United Kingdom.#13 - Uranium EnergyNYSEAMERICAN:UECStock Price: $7.40 (+$0.42)P/E Ratio: -740.00Market Cap: $2.99 billionAverage Trading Volume: 7.44 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.80 (18.9% Upside)Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing uranium and titanium concentrates in the United States, Canada, and Paraguay. It owns interests in the Palangana mine, Goliad, Burke Hollow, Longhorn, and Salvo projects located in Texas; Anderson, Workman Creek, and Los Cuatros projects situated in Arizona; Dalton Pass and C de Baca project located in New Mexico; Roughrider, Shea Creek, Christie Lake, Horseshoe-Raven, Hidden Bay, Diabase, West Bear, JCU, and other project located in Canada; and Yuty, Oviedo, and Alto Paraná titanium projects in Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. Uranium Energy Corp. was incorporated in 2003 and is headquartered in Corpus Christi, Texas.#14 - Centerra GoldNYSE:CGAUStock Price: $7.19 (+$0.21)P/E Ratio: 26.63Market Cap: $1.54 billionAverage Trading Volume: 413,354 sharesDividend Yield: 3.07%<Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.40 (30.7% Upside)Centerra Gold Inc., a gold mining company, engages in the acquisition, exploration, development, and operation of gold and copper properties in North America, Turkey, and internationally. The company explores for gold, copper, and molybdenum deposits. Its flagship projects are the 100% owned Mount Milligan gold-copper mine located in British Columbia, Canada; and the Öksüt gold mine located in Turkey. The company was incorporated in 2002 and is based in Toronto, Canada.#15 - Adverum BiotechnologiesNASDAQ:ADVMStock Price: $7.88 (-$0.37)P/E Ratio: -0.77Market Cap: $163.59 millionAverage Trading Volume: 269,364 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $29.00 (268.0% Upside)Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.#16 - St. James's PlaceOTCMKTS:STJPFStock Price: $6.15P/E Ratio: 21.67Average Trading Volume: 3,132 sharesDividend Yield: 2.36%<Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1,767.00 (28,624.0% Upside)St. James's Place plc is a publicly owned investment manager. The firm launches and manages equity, fixed income, and balanced mutual funds for its clients. It invests in public equity and fixed income market across the globe. The firm was formerly known as St. James's Place Capital plc. St. James's Place plc was founded in 1991 and is based in Cirencester, United Kingdom.“Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now.#17 - Carisma TherapeuticsNASDAQ:CARMStock Price: $1.39 (+$0.02)P/E Ratio: -0.70Market Cap: $57.74 millionAverage Trading Volume: 155,917 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.60 (518.7% Upside)Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.#18 - RedwireNYSE:RDWStock Price: $4.92 (+$0.05)P/E Ratio: -6.83Market Cap: $322.65 millionAverage Trading Volume: 221,655 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.75 (37.2% Upside)Redwire Corporation provides critical space solutions and space infrastructure for government and commercial customers in the United States, Europe, and internationally. The company provides avionics and sensors including star trackers, sun sensors, critical for navigation, and control of spacecraft; camera systems; solar array solutions for spacecraft spanning the spectrum of size, power needs, and orbital location; and strain composite booms, coilable booms, truss structures, telescope baffles, and deployable booms to position sensors or solar arrays away from the spacecraft. It offers software suite that enables digital engineering and generation of high-fidelity, interactive modeling and simulations of individual components, entire spacecraft, and full constellations in a cloud-based environment. In addition, the company microgravity payloads, radio frequency systems, antennas, star trackers, platforms, and in-space manufacturing and biotech facilities. Redwire Corporation is headquartered in Jacksonville, Florida.#19 - Gambling.com GroupNASDAQ:GAMBStock Price: $7.95 (+$0.11)P/E Ratio: 16.92Market Cap: $295.90 millionAverage Trading Volume: 156,188 sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.94 (87.9% Upside)Gambling.com Group Limited operates as a performance marketing company for the online gambling industry worldwide. It provides digital marketing services for the iGaming and social casino products. The company's focus is on online casino, online sports betting, and fantasy sports industry. It publishes various branded websites, including Gambling.com, Casinos.com, RotoWire.com, and Bookies.com. The company was incorporated in 2006 and is based in Saint Helier, Jersey.#20 - Man GroupOTCMKTS:MNGPFStock Price: $3.55P/E Ratio: 121.21Average Trading Volume: 1,233 sharesDividend Yield: 3.50%<Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $128.50 (3,519.7% Upside)Man Group Limited is a publicly owned investment manager. The firm provides long-only and alternative investment management services worldwide. It offers a range of liquid investment products and solutions, which include quantitative, multi-manager and discretionary investment styles, and span across various asset classes, like equity, real estate, currency, credit, volatility, and commodities. The firm distributes its products and solutions directly to institutions and to private investors through a global network of intermediaries. Man Group Limited was founded in 1783 and is based in St. Helier, Jersey with an additional office in London, United Kingdom.#21 - Perspective TherapeuticsNYSEAMERICAN:CATXStock Price: 1.62 (+0.09)Market Cap: $947.88 millionAverage Trading Volume: 4.21 million sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/APerspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.#22 - Genius SportsNYSE:GENIStock Price: $5.45P/E Ratio: -13.97Market Cap: $1.27 billionAverage Trading Volume: 2.17 million sharesConsensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.33 (71.3% Upside)Genius Sports Limited engages in the development and sale of technology-led products and services to the sports, sports betting, and sports media industries. It offers technology infrastructure for the collection, integration, and distribution of live data of sports leagues; streaming solutions comprising technology, automatic production, and distribution for sports to commercialize video footage of their games; and end-to-end integrity services to sports leagues, such as full-time active monitoring technology, which uses mathematical algorithms to identify and flag suspicious betting activity in global betting markets, as well as a full suite of online and offline educational and consultancy services. The company also provides live sports data collection; pre-game and in-game odds feeds; risk management services, including customer profiling, monitoring of incoming bets, automated acceptance and rejection of bets, and limit setting; live streaming services; creation, delivery, and optimization of digital marketing campaigns, such as data-driven personalized ad creative; and fan engagement widgets for digital publishers that offer live game statistics and betting-related content. The company is headquartered in London, the United Kingdom.#23 - COMPASS PathwaysNASDAQ:CMPSStock Price: $8.02 (+$0.03)P/E Ratio: -3.38Market Cap: $548.41 millionAverage Trading Volume: 634,846 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $47.40 (491.0% Upside)COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.#24 - Applied DigitalOTCMKTS:APLDStock Price: $3.66 (-$0.14)P/E Ratio: -7.47Market Cap: $449.55 millionAverage Trading Volume: 3.60 million sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.70 (301.6% Upside)Applied Digital Corporation designs, develops, and operates datacenters in North America. Its datacenters provide digital infrastructure solutions to the high-performance computing industry. The company also provides artificial intelligence cloud services, high performance computing datacenter hosting, and crypto datacenter hosting services. The company was formerly known as Applied Blockchain, Inc. and changed its name to Applied Digital Corporation in November 2022. Applied Digital Corporation is based in Dallas, Texas.#25 - Unicycive TherapeuticsNASDAQ:UNCYStock Price: $1.03P/E Ratio: -0.87Market Cap: $38.74 millionAverage Trading Volume: 353,200 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.30 (414.6% Upside)Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Gamestop is Heading Back to $10 or Lower Bargain Alert: Lululemon Shares Could Be About To Hit Rally Mode Bears Sent a False Alarm for Under Armour Stock Analysts Still Want Double-Digit Upside Out of Applied Materials Baidu Stock Earnings Prove Ray Dalio Right about China? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook The Real Reason Michael Burry is Buying Physical Gold Stocks With Subscription Based Revenue Offer Inflation Protection Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.